Few words create more uncertainty in medical cannabis than "unlicensed."

For patients, healthcare professionals and even those working across the wider healthcare sector, the term often raises immediate concerns.

Is it safe? Has it been tested? Is it regulated?

These are understandable questions, but they are based on a common misunderstanding.

In everyday language, unlicensed can sound as though something is unregulated or unapproved. In UK healthcare, however, the term has a very specific legal meaning, and it does not mean that a medicine falls outside regulatory oversight.

Understanding this distinction is essential for anyone involved in medical cannabis, from clinicians and pharmacists to manufacturers, distributors and policymakers.

Key Takeaways

• In UK healthcare, "unlicensed" does not mean unregulated.
• Many unlicensed medicines are prescribed routinely across multiple areas of medicine.
• Cannabis-based medicines prescribed as unlicensed medicines operate within an established legal and regulatory framework.
• Specialist doctors are responsible for determining whether an unlicensed medicine is appropriate for an individual patient.
• Regulation, quality standards and clinical governance continue to apply throughout the prescribing and supply process.

What Does "Unlicensed" Mean in UK Medicine?

An unlicensed medicine is simply a medicine that does not hold a UK marketing authorisation for a particular indication or product.

That definition is very different from saying a medicine is unregulated.

Within UK pharmaceutical legislation, many unlicensed medicines are supplied as "Specials." These medicines may be prescribed by a specialist clinician when they determine that a licensed alternative does not adequately meet the clinical needs of an individual patient.

The term "unlicensed" describes the medicine's regulatory status, not its quality, safety or the standards under which it is manufactured.

Unlicensed Does Not Mean Unregulated

One of the biggest misconceptions surrounding medical cannabis is the belief that unlicensed medicines exist outside regulatory oversight.

They do not.

The UK has a well-established legal framework governing the manufacture, supply and prescribing of unlicensed medicines.

For cannabis-based medicines supplied as Specials, this includes:

• Oversight by the Medicines and Healthcare products Regulatory Agency (MHRA)
• Manufacture under Good Manufacturing Practice (GMP) standards
• Appropriate licensing for manufacturers supplying Specials
• Compliance with UK pharmaceutical regulations and guidance

These requirements help ensure medicines are produced and supplied within a robust regulatory environment.

Unlicensed Prescribing Is Already Part of UK Healthcare

Unlicensed prescribing is not unique to medical cannabis.

For decades, clinicians have prescribed unlicensed medicines across a range of specialties where they believe it is in the patient's best interests.

Examples include:

• Paediatrics
• Oncology
• Palliative care
• Rare disease management

In each case, the legal framework allows specialist clinicians to prescribe an unlicensed medicine where there is no suitable licensed alternative for that individual patient's needs.

Medical cannabis follows the same established principles.

Who Can Prescribe Unlicensed Cannabis-Based Medicines?

Not every healthcare professional can initiate a prescription for an unlicensed cannabis-based medicine.

In the UK, initial prescriptions must be issued by a doctor listed on the GMC Specialist Register, following an individual clinical assessment.

This reflects the specialist nature of prescribing cannabis-based medicines and ensures that prescribing decisions are made by clinicians with appropriate expertise.

Treatment decisions should always be based on:

• The patient's clinical presentation
• Medical history
• Previous treatments
• Individual therapeutic need
• The availability of suitable licensed alternatives

When Are Unlicensed Medicines Considered?

Unlicensed medicines are not used as first-line treatments simply because they are available.

Instead, they may be considered only after an individual clinical assessment and where a specialist determines that no suitable licensed medicine adequately meets the patient's needs.

This patient-centred approach reflects established principles of prescribing across UK healthcare.

The decision is always based on clinical judgement, not product availability alone.

The Role of NICE and Clinical Guidance

Prescribing decisions do not occur in isolation.

Specialist clinicians work within national guidance, professional standards and regulatory frameworks.

For cannabis-based medicines, this includes relevant NICE guidance, which outlines the framework within which prescribing decisions are made for specific clinical indications.

Alongside NICE guidance, clinicians also consider the available evidence, patient-specific factors and evolving clinical experience.

Why Understanding "Unlicensed" Matters

Language shapes confidence.

When the word "unlicensed" is misunderstood, it can discourage meaningful conversations about treatment options and create unnecessary uncertainty among patients, healthcare professionals and policymakers.

Improving understanding is therefore about more than defining a regulatory term.

It is about ensuring discussions around cannabis-based medicines are informed by the legal and clinical framework that already exists.

As the medical cannabis sector continues to evolve, accurate communication will be just as important as scientific evidence in building confidence across healthcare.

What This Means for the Medical Cannabis Industry

For the industry, the focus should not be on explaining away the word "unlicensed."

Instead, it should be on explaining the regulatory safeguards, clinical governance and prescribing framework that support the use of cannabis-based medicines in appropriate patients.

As clinical evidence continues to grow and healthcare professionals gain greater experience, transparency will remain fundamental to building trust across the sector.

The future of medical cannabis depends not only on innovation, but also on helping clinicians, regulators and the public understand the systems already in place to support safe and responsible prescribing.

Frequently Asked Questions

Does "unlicensed" mean a medicine is unsafe?

No. An unlicensed medicine is not the same as an unsafe medicine. The term refers to its regulatory status, while manufacture, supply and prescribing remain subject to strict legal and regulatory requirements.

What is a "Special" in UK medicine?

A Special is an unlicensed medicine supplied to meet the specific clinical needs of an individual patient when no suitable licensed alternative is available.

Who can prescribe unlicensed cannabis-based medicines?

Initial prescriptions for unlicensed cannabis-based medicines must be issued by doctors on the GMC Specialist Register following an individual clinical assessment.

Are unlicensed medicines regulated?

Yes. Unlicensed medicines remain subject to regulatory oversight, including MHRA requirements, manufacturing standards and legal prescribing frameworks.

Conclusion

The word "unlicensed" has become one of the biggest barriers to understanding medical cannabis, but it should not be.

Within UK healthcare, unlicensed medicines are part of a long-established prescribing framework used across multiple medical specialties when specialist clinicians determine they are the most appropriate option for an individual patient.

Understanding that distinction is essential.

Because informed conversations lead to informed decisions, and informed decisions are fundamental to building confidence in evidence-based medical cannabis.